Trials / Completed
CompletedNCT00458562
Identifying Genes That Predict Risk of Developing Cervical Intraepithelial Neoplasia or Invasive Cervical Cancer
HIV-Associated DNA Hypermethylation in Cervical Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,680 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Finding certain changes in genes may help doctors predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying genes that may predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer.
Detailed description
OBJECTIVES: * Utilize molecular assays to identify a panel of hypermethylated genes that are predictive of cervical intraepithelial neoplasia (CIN) grade 3 or invasive cervical cancer (ICC) among patients with or without HIV infection. * Perform a nested case-control study assessing the risk of developing CIN3 in relationship to human papillomavirus (HPV) persistence, HIV, and the presence or acquisition of candidate hypermethylated genes in these patients. * Identify HIV-related factors (e.g., CD4 counts, viral load, and highly active antiretroviral therapy \[HAART\]) that might be associated with the presence or acquisition of specific hypermethylated genes in these patients. OUTLINE: This is a longitudinal, multicenter study. Patients undergo biopsy for removal of cervical tissue. Patients also undergo blood and urine sample collection. Samples are analyzed for the presence of cancer or changes that indicate that cancer might develop. Patients also undergo colposcopy at baseline and at 3 years. After completion of study procedures, patients are followed every 4 months for up to 3 years. PROJECTED ACCRUAL: A total of 1,150 patients will be accrued for this study.
Conditions
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2007-04-11
- Last updated
- 2013-11-19
Locations
2 sites across 1 country: Senegal
Source: ClinicalTrials.gov record NCT00458562. Inclusion in this directory is not an endorsement.